StockData
CRISPR Therapeutics AG logo

CRISPR Therapeutics AG (CRSP) stock

CRSPNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$40.15−0.22 (-0.54%)

Close on Nov 17, 2026Market cap $3.88BP/E –Yield –

CRISPR Therapeutics cash

Cash and short-term investments held at the end of each period.

CRISPR Therapeutics's cash was $2.36B at Jun 30, 2026. For fiscal 2025 it was $1.98B, up 3.8% from the year before. Over ten years it grew 28.9% a year on average. The highest annual figure on record is $2.38B in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.98B+3.8%
FY2024Dec 31, 2024$1.90B+12.4%
FY2023Dec 31, 2023$1.69B-6.7%
FY2022Dec 31, 2022$1.82B-23.7%
FY2021Dec 31, 2021$2.38B+40.7%
FY2020Dec 31, 2020$1.69B+79.1%
FY2019Dec 31, 2019$943.77M+106.7%
FY2018Dec 31, 2018$456.65M+90.5%
FY2017Dec 31, 2017$239.76M-24.0%
FY2016Dec 31, 2016$315.52M+102.3%
FY2015Dec 31, 2015$155.96M+16403.8%
FY2014Dec 31, 2014$945.00K+161.8%
FY2013Dec 31, 2013$361.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.36B+37.4%
Q1 FY2026Mar 31, 2026$2.44B+31.6%
Q4 FY2025Dec 31, 2025$1.98B+3.8%
Q3 FY2025Sep 30, 2025$1.92B-1.0%
Q2 FY2025Jun 30, 2025$1.72B-14.0%
Q1 FY2025Mar 31, 2025$1.86B-12.0%
Q4 FY2024Dec 31, 2024$1.90B+12.4%
Q3 FY2024Sep 30, 2024$1.94B+11.3%
Q2 FY2024Jun 30, 2024$2.00B+13.2%
Q1 FY2024Mar 31, 2024$2.11B+11.9%
Q4 FY2023Dec 31, 2023$1.69B-6.7%
Q3 FY2023Sep 30, 2023$1.74B-8.2%
Q2 FY2023Jun 30, 2023$1.77B-14.4%
Q1 FY2023Mar 31, 2023$1.88B-15.2%
Q4 FY2022Dec 31, 2022$1.82B-23.7%
Q3 FY2022Sep 30, 2022$1.90B-23.5%
Q2 FY2022Jun 30, 2022$2.07B-20.2%
Q1 FY2022Mar 31, 2022$2.22B+23.0%
Q4 FY2021Dec 31, 2021$2.38B+40.7%
Q3 FY2021Sep 30, 2021$2.48B+81.4%
Q2 FY2021Jun 30, 2021$2.59B+174.0%
Q1 FY2021Mar 31, 2021$1.81B+103.0%
Q4 FY2020Dec 31, 2020$1.69B+79.1%
Q3 FY2020Sep 30, 2020$1.37B+116.9%
Q2 FY2020Jun 30, 2020$945.07M+120.9%
Q1 FY2020Mar 31, 2020$889.71M+103.3%
Q4 FY2019Dec 31, 2019$943.77M+106.7%
Q3 FY2019Sep 30, 2019$629.72M+29.2%
Q2 FY2019Jun 30, 2019$427.89M+33.8%
Q1 FY2019Mar 31, 2019$437.55M+28.0%
Q4 FY2018Dec 31, 2018$456.65M+90.5%
Q3 FY2018Sep 30, 2018$487.30M+92.2%
Q2 FY2018Jun 30, 2018$319.74M+17.4%
Q1 FY2018Mar 31, 2018$341.77M+17.0%
Q4 FY2017Dec 31, 2017$239.76M-24.0%
Q3 FY2017Sep 30, 2017$253.52M+10.9%
Q2 FY2017Jun 30, 2017$272.26M–
Q1 FY2017Mar 31, 2017$292.02M–
Q4 FY2016Dec 31, 2016$315.52M–
Q3 FY2016Sep 30, 2016$228.61M–

More CRISPR Therapeutics figures

See a number that looks wrong?